Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective
Clinical and Experimental Medicine · 08.07.2025 · 25 (1)
DOI: 10.1007/s10238-025-01751-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 08.07.2025. Verfasst von Negar Sadat Sherafat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Angiogenesis Inhibitors. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 249 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs (AADs) holds promise in cancer treatment. While ICIs block signals that help cancer cells evade the immune system, anti-angiogenic agents target blood vessels, limiting tumor growth by restricting nutrient and oxygen supplies. Additionally, the judicious use of AADs can normalize the tumor vasculature, alleviate hypoxia, and enhance the antitumor immune response. As the shutdown of a single target does not necessarily eradicate cancer, the use of combinations of molecular-targeted agents has been proposed, and some pioneering research has been conducted to examine the efficacy of this strategy. The combination of these two modalities offers a synergistic approach, enhancing the efficacy of tumor eradication. Recent studies have elucidated the rationale behind this combination therapy, but a limited response rate has been achieved with monotherapy. Clinical trials have demonstrated the potential of this combination, with improved outcomes in various solid tumor types. The dual blockade of angiogenesis and immune checkpoints is poised to become a standard of care, with indications expected to expand as more evidence accumulates. The antitumor efficacy of current therapies is limited, most likely because of the high degree of cancer clonal heterogeneity, intratumor genetic heterogeneity, and cell signal complexity. Although numerous studies have been conducted in this area, this review provides a comprehensive analysis of the molecular rationale for ICIs and AADs in cancer therapy. We not only compare the individual properties and mechanisms of both treatments, but also explore their complementary roles, which are essential for optimizing personalized treatment strategies. By addressing key challenges such as tumor heterogeneity, immune evasion, and resistance to monotherapies, we demonstrate how this combination approach can enhance treatment outcomes. Furthermore, we incorporate the latest preclinical and clinical findings and offer future perspectives on optimizing drug selection, dosing, and treatment design to maximize therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Zitieren
APA
Sherafat, N. S., Keshavarz, A., Mardi, A., Mohammadiara, A., Aghaei, M., Aghebati-Maleki, L., & Mohammadi, M. H. (2025). Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-025-01751-7
Vancouver
Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clinical and Experimental Medicine. 2025;25(1). doi:10.1007/s10238-025-01751-7
BibTeX
@article{Sherafat2025,
author = {Sherafat, Negar Sadat and Keshavarz, Ali and Mardi, Amirhossein and Mohammadiara, Amirmohammad and Aghaei, Mojtaba and Aghebati-Maleki, Leili and Mohammadi, Mohammad Hossein},
title = {Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective},
journal = {Clinical and Experimental Medicine},
year = {2025},
volume = {25},
number = {1},
doi = {10.1007/s10238-025-01751-7}
}
EUVIMED